Vertex Pharmaceuticals (VRTX +4.8%) finishes higher today after saying it's entered into a...

|About: Vertex Pharmaceuticals Inco... (VRTX)|By:, SA News Editor

Vertex Pharmaceuticals (VRTX +4.8%) finishes higher today after saying it's entered into a non-exclusive agreement with GlaxoSmithKline (GSK) to conduct a Phase 2 study of an all-oral regimen for the treatment of hepatitis C containing Vertex's nucleotide analogue hepatitis C virus polymerase inhibitor VX-135 and GSK's NS5A inhibitor GSK2336805. The study is expected to begin in early 2013, pending discussions with regulatory authorities.